[1]
|
Cho, N.H., Shaw, J.E., Karuranga, S., et al. (2018) IDF Diabetes Atlas: Global Estimates of Diabetes Prevalence for 2017 and Projections for 2045. Diabetes Research and Clinical Practice, 138, 271-281.
https://doi.org/10.1016/j.diabres.2018.02.023
|
[2]
|
Grøndahl, M.F.G., Johannesen, J., Kristensen, K., et al. (2021) Treatment of Type 2 Diabetes in Children: What Are the Specific Considerations. Expert Opinion on Pharmacotherapy, 22, 2127-2141.
https://doi.org/10.1080/14656566.2021.1954160
|
[3]
|
Demir, S., Nawroth, P.P., Herzig, S., et al. (2021) Emerging Targets in Type 2 Diabetes and Diabetic Complications. Advanced Science (Weinh), 8, e2100275. https://doi.org/10.1002/advs.202100275
|
[4]
|
Ogurtsova, K., da Rocha Fernandes, J.D., Huang, Y., et al. (2017) IDF Diabetes Atlas: Global Estimates for the Prevalence of Diabetes for 2015 and 2040. Diabetes Research and Clinical Practice, 128, 40-50.
https://doi.org/10.1016/j.diabres.2017.03.024
|
[5]
|
Taylor, R. (2008) Pathogenesis of Type 2 Diabetes: Tracing the Reverse Route from Cure to Cause. Diabetologia, 51, 1781-1789. https://doi.org/10.1007/s00125-008-1116-7
|
[6]
|
Taylor, R. (2021) Type 2 Diabetes and Remission: Practical Management Guided by Pathophysiology. Journal of Internal Medicine, 289, 754-770. https://doi.org/10.1111/joim.13214
|
[7]
|
Batista, T.M., Haider, N. and Kahn, C.R. (2021) Defining the Underlying Defect in Insulin Action in Type 2 Diabetes. Diabetologia, 64, 994-1006. https://doi.org/10.1007/s00125-021-05415-5
|
[8]
|
Costes, S., Bertrand, G. and Ravier, M.A. (2021) Mechanisms of Beta-Cell Apoptosis in Type 2 Diabetes-Prone Situations and Potential Protection by GLP-1-Based Therapies. In-ternational Journal of Molecular Sciences, 22, 5303.
https://doi.org/10.3390/ijms22105303
|
[9]
|
Halban, P.A., Polonsky, K.S., Bowden, D.W., et al. (2014) β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment. Diabetes Care, 37, 1751-1758. https://doi.org/10.2337/dc14-0396
|
[10]
|
Moin, A.S.M. and Butler, A.E. (2019) Alterations in Beta Cell Identity in Type 1 and Type 2 Diabetes. Current Diabetes Reports, 19, 83. https://doi.org/10.1007/s11892-019-1194-6
|
[11]
|
Wang, J., Ma, Q., Li, Y., et al. (2020) Research Progress on Traditional Chinese Medicine Syndromes of Diabetes Mellitus. Biomedicine & Pharmacotherapy, 121, Article ID: 109565. https://doi.org/10.1016/j.biopha.2019.109565
|
[12]
|
郭小舟, 陶夏平, 王斌. 从湿热瘀毒论治糖尿病[J]. 中国中医基础医学杂志, 2021, 27(6): 1017-1018+1021.
|
[13]
|
杨梦依, 倪海祥. 从湿热论治新诊断2型糖尿病[J]. 浙江中西医结合杂志, 2021, 31(11): 1071-1074.
|
[14]
|
严龙. 中药仙茅在大鼠体内的PK-PD模型初探[D]: [硕士学位论文]. 曲阜: 曲阜师范大学, 2014.
|
[15]
|
杨彬, 马景, 俞恒桑, 等. 凉膈散与黄连解毒汤对2型糖尿病小鼠血糖、血脂及胰岛素水平的影响[J]. 浙江中西医结合杂志, 2009, 19(6): 337-338.
|
[16]
|
黄秀芳, 陶彦谷, 张茹兰, 等. 黄连解毒汤对胰岛素抵抗大鼠炎症因子和氧化应激水平的影响[J]. 中国中医药科技, 2017, 24(5): 572-574+583.
|
[17]
|
苟芳, 张红军, 王洁, 等. 黄连解毒汤通过抑制TGF-β信号通路减轻2型糖尿病大鼠肝脂肪变性和纤维化研究[J]. 陕西中医, 2022, 43(2): 170-176.
|
[18]
|
刘巧, 胡慧玲, 岳青, 等. 三黄泻心汤对II型糖尿病大鼠的降血糖作用研究[J]. 中药与临床, 2018, 9(2): 43-47.
|
[19]
|
张益钧, 沈利水, 戴盛锋, 等. 三黄汤与普济消毒饮干预2型糖尿病小鼠胰岛素信号错误转导的机理研究[J]. 中医药学报, 2009, 37(2): 25-28.
|
[20]
|
Furman, B.L., Candasamy, M., Bhattamisra, S.K., et al. (2020) Reduction of Blood Glucose by Plant Extracts and Their Use in the Treatment of Diabetes Mellitus: Discrepancies in Effectiveness between Animal and Human Studies. Journal of Ethnopharmacology, 247, Article ID: 112264. https://doi.org/10.1016/j.jep.2019.112264
|
[21]
|
黄永亮, 吴纯洁, 何晓燕. 中药提取工艺评价指标的研究进展[J]. 中药与临床, 2012, 3(5): 49-52.
|
[22]
|
Cui, X., Qian, D.W., Jiang, S., et al. (2018) Scutellariae Radix and Coptidis Rhizoma Improve Glucose and Lipid Metabolism in T2DM Ratsvia Regulation of the Metabolic Profiling and MAPK/PI3K/Akt Signaling Pathway. International Journal of Molecular Sciences, 19, 3634. https://doi.org/10.3390/ijms19113634
|
[23]
|
Xiao, S., Liu, C., Chen, M., et al. (2020) Scutellariae Radix and Coptidisrhizoma Ameliorate Glyeolipid Metabolism of Type 2 Diabetic Rats by Modulating Gut Microbiota and Its Metabolites. Applied Microbiology and Biotechnology, 104, 303-317. https://doi.org/10.1007/s00253-019-10174-w
|
[24]
|
郭志利, 左晓琦, 张梅, 等. 黄连对2型糖尿病大鼠调节性T细胞及相关炎症因子的影响[J]. 现代中西医结合杂志, 2022, 31(5): 619-623+717.
|
[25]
|
Yu, M., Han, S., Wang, M., et al. (2022) Baicalin Protects against Insulin Resistance and Metabolic Dysfunction through Activation of GALR2/GLUT4 Signaling. Phytomedicine, 95, Article ID: 153869.
https://doi.org/10.1016/j.phymed.2021.153869
|
[26]
|
闫爽, 李光耀, 戴丛书, 等. 蒲公英提取物对2型糖尿病大鼠降血糖的作用[J]. 食品与机械, 2020, 36(11): 138-142.
|
[27]
|
王成祥, 刘玉霞, 常绍鸿, 等. 马齿苋多糖对幼年糖尿病大鼠糖脂代谢、肾功能的影响及其作用机制[J]. 中国医科大学学报, 2021, 50(1): 46-50+56.
|
[28]
|
鱼晓敏, 安馨, 鲁慧, 王兴婷, 江岩. 桑叶水提物与醇提物对糖尿病小鼠的协同降血糖效应[J]. 卫生研究, 2018, 47(3): 432-436
|
[29]
|
孙文杰, 赵能江, 李博, 等. 《中国2型糖尿病防治指南(2020年版)》推荐中成药品种述评[J]. 中国中医药信息杂志, 2022, 29(3): 1-5.
|
[30]
|
马明华, 戴媛媛, 汪晓河, 等. 2015年版中国药典收载的治疗糖尿病的中成药组方药味特点研究[J]. 上海医药, 2020, 41(3): 31-34.
|
[31]
|
杨亚男, 李艳杰, 陈玉鹏, 等. 已上市中成药治疗糖尿病的用药规律及核心处方挖掘[J]. 世界中医药, 2022, 17(3): 418-423.
|
[32]
|
王芳玲, 田风胜, 王元松, 等. 三黄片对糖尿病模型大鼠氧化应激水平的影响实验[J]. 河北中医, 2015, 37(7): 1031-1034.
|
[33]
|
周金芳, 宋菊敏, 刘小美, 等. 复方黄连降糖片对GK大鼠糖脂代谢紊乱的影响[J]. 辽宁中医药大学学报, 2011, 13(4): 110-112.
|
[34]
|
魏萍. 基于InsR-PI3K-Akt信号通路探讨金芪降糖片改善细胞胰岛素抵抗的机制[D]: [硕士学位论文]. 北京: 北京中医药大学, 2021.
|
[35]
|
唐程, 朴春丽, 王丽, 等. 糖尿病前期中西医治疗进展[J]. 吉林中医药, 2021, 41(3): 416-420.
|
[36]
|
路建刚. 中西医结合治疗2型糖尿病的临床效果观察[J]. 黑龙江科学, 2022, 13(4): 132-133.
|